Last reviewed · How we verify
Anastozole (Arimidex)
Anastrozole is a non-steroidal aromatase inhibitor that blocks the conversion of androgens to estrogen in postmenopausal women with hormone receptor-positive breast cancer.
Anastrozole is a non-steroidal aromatase inhibitor that blocks the conversion of androgens to estrogen in postmenopausal women with hormone receptor-positive breast cancer. Used for Adjuvant treatment of hormone receptor-positive early-stage breast cancer in postmenopausal women, First-line treatment of advanced breast cancer in postmenopausal women, Extended therapy following tamoxifen in postmenopausal women with early-stage breast cancer.
At a glance
| Generic name | Anastozole (Arimidex) |
|---|---|
| Also known as | Arimidex |
| Sponsor | AstraZeneca |
| Drug class | Aromatase inhibitor (non-steroidal) |
| Target | Aromatase (CYP19A1) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Anastrozole selectively inhibits the aromatase enzyme, which catalyzes the final step of estrogen synthesis in peripheral tissues. By reducing circulating estrogen levels, it deprives estrogen-dependent breast cancer cells of growth signals. This mechanism is particularly effective in postmenopausal women where aromatase is the primary source of estrogen production.
Approved indications
- Adjuvant treatment of hormone receptor-positive early-stage breast cancer in postmenopausal women
- First-line treatment of advanced breast cancer in postmenopausal women
- Extended therapy following tamoxifen in postmenopausal women with early-stage breast cancer
Common side effects
- Hot flashes
- Arthralgia/joint pain
- Fatigue
- Headache
- Vaginal dryness
- Osteoporosis/bone loss
- Elevated cholesterol
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anastozole (Arimidex) CI brief — competitive landscape report
- Anastozole (Arimidex) updates RSS · CI watch RSS
- AstraZeneca portfolio CI